What is LinkBio?
LinkBio, operating within the orthopedics industry, is dedicated to the development and manufacturing of high-quality, bioharmonious prostheses for primary and revision arthroplasty of major joints. The company's product portfolio encompasses solutions for hip, knee, and upper extremity joint replacements, aiming to significantly improve patient quality of life through enhanced mobility and pain reduction. With a legacy spanning over five decades and a global presence in more than 70 countries, LinkBio emphasizes manufacturing excellence and stringent quality control. Their commitment extends to fostering the next generation of industry professionals and pioneering advancements in joint replacement technology.
How much funding has LinkBio raised?
LinkBio has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
What's next for LinkBio?
The substantial late-stage funding received by LinkBio is poised to accelerate its strategic growth initiatives. This capital injection will likely fuel further research and development into next-generation prosthetics, expand manufacturing capabilities, and broaden its international market reach. The company's focus on innovation and quality positions it for continued leadership in the competitive field of joint arthroplasty, with potential for further strategic partnerships and market penetration.
See full LinkBio company page
